Human Epidermal Growth Factor Receptor 2 Alterations and Prognostic Implications in All Subtypes of Breast Cancers
JCO Precision Oncology · 2025
DOI: 10.1200/po.23.00719 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2025. Verfasst von Arielle L Heeke und 13 weiteren Autor:innen. Beteiligte Einrichtung: Levine Cancer Institute, Atrium Health, Charlotte, NC. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Alterations in human epidermal growth factor receptor 2 (HER2; ERBB2 gene) may be clinically relevant when considering HER2-targeted therapies. We have characterized the breadth of ERBB2 alterations (mutation, fusion, and copy number amplification) in breast cancer and explored the relationship between ERBB2 alterations and prognosis. METHODS DNA next-generation sequencing (592-gene panel and whole-exome sequencing) and RNA whole-transcriptome sequencing data from 12,153 breast samples were retrospectively reviewed for ERBB2 alterations. Clinicopathologic features were described, including breast cancer subtype, age, and biopsy site. HER2 status was determined according to ASCO guideline recommendations, including HER2-low. Overall survival (OS) data were obtained from insurance claims, and Kaplan-Meier estimates were calculated for defined patient cohorts. Statistical significance was determined using chi-square and Wilcoxon rank-sum tests. RESULTS Pathogenic ERBB2 mutations ( ERBB2- mut) were identified in 3.2% (N = 388) of tumors overall, most common in liver metastases (113/1,972, 5.7%). ERBB2- mut was more common among breast lobular than ductal (10% v 2.1%; P < .001) and HER2-positive (HER2+)/low tumors (≥3.8% v 1.5% TNBC; P < .05). The most common variant was ERBB2 -L755S (1.0% prevalence), enriched in metastatic tumors (1.2% v 0.6% in primary; P < .001). ERBB2 fusions were rare (0.3% prevalence). Coalterations associated with ERBB2 -mutated tumors compared with ERBB2 wildtype (WT) included CDH1 (40.0% v 10.2%; P < .001) and ERBB3 (10.6% v 0.8%; P < .001). Of the 10,115 tumor samples with outcome data, ERBB2- mut was associated with worse OS compared with WT. CONCLUSION ERBB2- mut and fusions were observed in all breast cancer subtypes—more commonly in HER2+/low, metastatic, and lobular histology tumors—and associated with poorer prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Levine Cancer Institute, Atrium Health, Charlotte, NC.
- Caris Life Sciences, Phoenix, AZ.
- Department of Cancer Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, NC.
- City of Hope Orange County, Irvine, CA.
- Saint John's Cancer Institute, Saint John's Health Center, Providence Health Systems, Santa Monica, CA.
- University of Texas MD Anderson Cancer Center, Houston, TX.
ORCID-Profile: Arielle L Heeke, James T Symanowski, Irene M Kang, George W Sledge, Milan Radovich, Paula R Pohlmann, Sandra M Swain, Antoinette R Tan
Zitieren
APA
Heeke, A. L., Elliott, A., O'Keefe, K., Livasy, C., Symanowski, J. T., Steiner, M. R., Kang, I. M., Hoon, D. S. B., Walker, P., Sledge, G. W., Radovich, M., Pohlmann, P. R., Swain, S. M., & Tan, A. R. (2025). Human Epidermal Growth Factor Receptor 2 Alterations and Prognostic Implications in All Subtypes of Breast Cancers. JCO Precision Oncology. https://doi.org/10.1200/po.23.00719
Vancouver
Heeke AL, Elliott A, O'Keefe K, Livasy C, Symanowski JT, Steiner MR, et al. Human Epidermal Growth Factor Receptor 2 Alterations and Prognostic Implications in All Subtypes of Breast Cancers. JCO Precision Oncology. 2025. doi:10.1200/po.23.00719
BibTeX
@article{Heeke2025,
author = {Heeke, Arielle L and Elliott, Andrew and O'Keefe, Kaitlyn and Livasy, Chad and Symanowski, James T and Steiner, Meghan R and Kang, Irene M and Hoon, Dave S B and Walker, Philip and Sledge, George W and Radovich, Milan and Pohlmann, Paula R and Swain, Sandra M and Tan, Antoinette R},
title = {Human Epidermal Growth Factor Receptor 2 Alterations and Prognostic Implications in All Subtypes of Breast Cancers},
journal = {JCO Precision Oncology},
year = {2025},
doi = {10.1200/po.23.00719}
}
EUVIMED